Merrylee McGuffin
Overview
Explore the profile of Merrylee McGuffin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Udovicich C, Cheung P, Chu W, Chung H, Detsky J, Liu S, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39904690
Background And Objective: Recent randomized controlled trials have demonstrated the efficacy of five-fraction stereotactic body radiotherapy (5F-SBRT) for prostate cancer (PC), but there is no comparative evidence for fewer fractions....
2.
Chan A, Hoang A, Chen H, McGuffin M, Vesprini D, Zhang L, et al.
Adv Radiat Oncol
. 2024 Nov;
9(12):101651.
PMID: 39524526
Purpose: Surface guided radiation therapy (SGRT) in breast cancer radiation therapy (RT) may decrease the need for image guidance such as cone beam computed tomography (CBCT). The goal of this...
3.
Peng J, Partanen A, Pichardo S, Staruch R, Perry K, McGuffin M, et al.
Int J Hyperthermia
. 2024 Jun;
41(1):2365385.
PMID: 38897584
Introduction: Pelvic recurrences from rectal cancer present a challenging clinical scenario. Hyperthermia represents an innovative treatment option in combination with concurrent chemoradiation to enhance therapeutic effect. We provide the initial...
4.
Hudson J, Loblaw A, McGuffin M, Chung H, Tseng C, Helou J, et al.
Radiother Oncol
. 2024 Jun;
198:110381.
PMID: 38879130
Background And Purpose: High dose-rate (HDR) brachytherapy as a monotherapy is an accepted treatment for localized prostate cancer, but the optimal dose and fractionation schedule remain unknown. We report on...
5.
Kennedy S, Dawdy K, Cao X, McGuffin M, Bristow B, Szumacher E
J Med Imaging Radiat Sci
. 2023 Sep;
54(4):583-589.
PMID: 37673706
Background: The aim of this study was to investigate patient engagement (PE) in the development and delivery of Continuing Professional Development (CPD) programs for health care providers within radiation oncology,...
6.
Ong W, Davidson M, Cheung P, Chung H, Chu W, Detsky J, et al.
Radiother Oncol
. 2023 Aug;
188:109864.
PMID: 37619656
Purpose: There is no evidence-based data to guide dose constraints in two-fraction prostate stereotactic ablative radiotherapy (SABR). Using individual patient-data from two prospective trials, we aimed to correlate dosimetric parameters...
7.
Ong W, Cheung P, Chung H, Chu W, Detsky J, Liu S, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jul;
117(5):1153-1162.
PMID: 37419394
Purpose: Focal boost to dominant intraprostatic lesion (DIL) is an approach for dose escalation in prostate radiation therapy. In this study, we aimed to report the outcomes of 2-fraction SABR...
8.
Wong J, McGuffin M, Smith M, Loblaw D
J Med Imaging Radiat Sci
. 2023 Jun;
54(3):429-435.
PMID: 37268549
Background: Patients having radiation therapy treatment to the prostate may require invasive preparation procedures under local anesthesia (LA), such as the insertion of gold seeds into the prostate or targeted...
9.
Ong W, Cheung P, Chung H, Chu W, Detsky J, Liu S, et al.
Radiother Oncol
. 2023 Feb;
181:109503.
PMID: 36754232
Purpose: This is the first report of the 2SMART Phase II trial evaluating the safety of two-fraction stereotactic ablative radiotherapy (SABR) with focal boost to magnetic resonance imaging (MRI) defined...
10.
Correa R, Morton G, Chung H, Tseng C, Cheung P, Chu W, et al.
Radiother Oncol
. 2022 Feb;
169:51-56.
PMID: 35151715
Background And Purpose: Contemporary radiotherapy for localized prostate cancer (PCa) is deliverable via stereotactic ablative radiotherapy (SABR) and high dose rate (HDR) brachytherapy. Here we report on a parallel cohort...